SEPULVEDA VIVEROS, DINO JOSE FRANCISCO

Preferred name
SEPULVEDA VIVEROS, DINO JOSE FRANCISCO
Main Affiliation
ORCID
0000-0002-5568-0950
Scopus Author ID
57410691500
Goggle Scholar

Settings

Now showing 1 - 5 of 5
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    A prognostic human brain network for diffuse midline glioma
    (Springer Science and Business Media LLC, 2026-06-10)
    Sidpra, Jai
    ;
    Lind, Valentina
    ;
    Cohen, Alexander L.
    ;
    Schaper, Frederic L. W. V. J.
    ;
    Stone, Thomas J.
      2
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Structural Enablers of Rare Disease Treatment Coverage in Latin America and the Caribbean: Lessons from Emicizumab
    (MDPI AG, 2026-02-25)
    Daniela Sugg Herrera
    ;
    SEPULVEDA VIVEROS, DINO JOSE FRANCISCO  
    ;
    Moisés Russo Namias
    ;
    Natalia Garrido
    <jats:p>We examine how structural characteristics of health systems in Latin America and the Caribbean (LAC) shape access to innovative therapies, using emicizumab for hemophilia A as a case study. Although the therapy is available in the region, access remains uneven and constrained by high costs and fragmented health system arrangements. Using a descriptive structural approach, we characterize the health system configurations associated with financial coverage of emicizumab across 16 LAC countries, representing more than 85% of the regional population. Regulatory approval timelines and coverage status were described, and principal component analysis (PCA) was applied to synthesize multiple indicators into a Global Characteristics Index capturing five core health system functions: resource generation, financing, service delivery, general governance, and therapy-specific governance. Coverage is defined as formal access with explicit financial protection provided by the health system. Substantial heterogeneity was observed across countries. Regulatory approval was often achieved relatively rapidly, but this did not consistently translate into timely or comprehensive coverage. Countries with stronger structural characteristics—particularly in resource generation, service delivery, and governance—tended to achieve broader and more sustained coverage, although institutional capacity alone was not sufficient in all cases. Our results emphasize the need to strengthen health governance and adopt specific policies for rare diseases in the region.</jats:p>
      2
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    CONSTRUCCIÓN Y VALIDACIÓN GUÍA PARA LAS BUENAS PRÁCTICAS DE COMUNICACIÓN DE RIESGO DURANTE CRISIS SANITARIAS
    (2024)
    Angelina Dois
    ;
    Loreto Fernández-González
    ;
    Alejandra Martínez-Pereira
    ;
    Luis Villarroel
    ;
    Moisés Russo
    <jats:p>INTRODUCCIÓN. La pandemia COVID-19 evidenció la necesidad de contar con estrategias de comunicación de riesgo efectivas y contextualizadas al territorio, para la toma de decisión informada de la comunidad. OBJETIVO. describir la construcción y validación por expertos de una Guía de Buenas Prácticas para Comunicación de Riesgo durante una crisis sanitaria (GBP-CR) en el contexto chileno. MATERIAL Y MÉTODOS. Estudio multi método y de validez de constructo para los elementos de evaluación de la guía. RESULTADOS. Se construyó una GBP-CR que aborda contenidos teóricos sobre comunicación de riesgo (CR), institucionalización de la estrategia, su enfoque y análisis del contexto de implementación. Incluye recomendaciones para construir, transmitir y evaluar el mensaje para una CR efectiva y rúbricas para valorar tres aspectos centrales de los comunicados. CONCLUSIÓN. Se construyó la primera Guía de Buenas Prácticas para la Comunicación de Riesgo durante una crisis sanitaria basada en evidencia y ajustada a la realidad local.</jats:p>
      1
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    Biosimilars approvals by thirteen regulatory authorities: A cross-national comparison
    (2023)
    Fernanda Lacerda da Silva Machado
    ;
    Martín Cañás
    ;
    Svetlana V. Doubova
    ;
    Martín A. Urtasun
    ;
    Gustavo H. Marín
    Scopus© Citations 9  1
  • Loading...
    Thumbnail Image
    Some of the metrics are blocked by your 
    consent settings
    Item type:Publication,
    A review of artificial intelligence in healthcare supply chains: untapped potential?
    (Springer Science and Business Media LLC, 2026-04-14)
    Espinosa, Oscar
    ;
    Basto, Sergio
    ;
    Ordóñez, Angélica
    ;
    Arias, Martha-Liliana
    ;
    SEPULVEDA VIVEROS, DINO JOSE FRANCISCO  
      1